TABLE 1.
In vitro activity of telavancin and other anti- Gram-positive comparator agents tested by reference methods against a worldwide collection of clinical S. aureus isolates
| Organism group (no. tested)/ antimicrobial agent | MIC50b | MIC90b | % Susceptible/resistanta |
|
|---|---|---|---|---|
| CLSI | EUCAST | |||
| MRSA (5,000) | ||||
| Telavancin | 0.12 | 0.25 | 100.0/—c | 100.0/ |
| Vancomycin | 1 | 1 | 99.9/0.0 | 99.9/0.1 |
| Teicoplanin | ≤2 | ≤2 | >99.9/<0.1 | 98.7/1.3 |
| Daptomycin | 0.25 | 0.5 | 99.9/— | 99.9/0.1 |
| Linezolid | 1 | 2 | >99.9/— | >99.9/<0.1 |
| Quinupristin-dalfopristin | 0.5 | 1 | 99.5/0.2 | 99.5/0.2 |
| Levofloxacin | >4 | >4 | 21.6/77.9 | 21.6/77.9 |
| Erythromycin | >4 | >4 | 13.9/85.6 | 14.2/85.6 |
| Clindamycin | ≤0.25 | >2 | 54.7/45.0 | 54.3/45.3 |
| Gentamicin | ≤1 | >8 | 77.9/21.1 | 77.1/22.9 |
| Tetracycline | ≤1 | >8 | 80.7/19.1 | 80.1/19.9 |
| TMP/SMX | ≤0.5 | ≤0.5 | 92.4/7.6 | 92.4/7.6 |
| MSSA (5,000) | ||||
| Telavancin | 0.12 | 0.25 | 100.0/— | 100.0/— |
| Vancomycin | 1 | 1 | 100.0/0.0 | 100.0/0.0 |
| Teicoplanin | ≤2 | ≤2 | 100.0/0.0 | 99.9/0.1 |
| Daptomycin | 0.25 | 0.5 | 100.0/— | 100.0/0.0 |
| Linezolid | 2 | 2 | 100.0/— | 100.0/0.0 |
| Quinupristin-dalfopristin | ≤0.25 | 0.5 | 99.9/0.0 | 99.9/0.0 |
| Levofloxacin | ≤0.5 | ≤0.5 | 92.9/6.8 | 92.9/6.8 |
| Erythromycin | ≤0.25 | >4 | 74.3/25.2 | 74.5/25.2 |
| Clindamycin | ≤0.25 | ≤0.25 | 95.0/4.9 | 94.6/5.0 |
| Gentamicin | ≤1 | ≤1 | 96.6/3.1 | 96.4/3.6 |
| Tetracycline | ≤1 | ≤1 | 94.6/5.0 | 94.2/5.8 |
| TMP/SMX | ≤0.5 | ≤0.5 | 98.7/1.3 | 98.7/1.3 |
a
The MIC interpretive criteria used were published by the CLSI (M100-S19) (3) and EUCAST (http://www.srga.org/eucastwt/MICTAB/index.html). The telavancin susceptibility breakpoint for S. aureus (≤1 μg/ml) was that recently approved by the U.S. FDA.
b
Values are in micrograms per milliliter.
c
—, no breakpoints available.